Park Lina, Tsai Yu-Tung, Lim Hyun-Kyoung, Faulhaber Lila D, Burleigh Katelyn, Faulhaber Eli M, Bose Mahashweta, Shih Andy Y, Hirayama Alexandre Y, Turtle Cameron J, Annesley Colleen E, Gardner Rebecca A, Gustafson Heather H, Gust Juliane
Norcliffe Foundation Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, Washington, USA.
bioRxiv. 2025 Feb 25:2025.02.19.638920. doi: 10.1101/2025.02.19.638920.
CD19-directed CAR T cells treat cancer, but also cause immune effector cell associated neurotoxicity syndrome (ICANS). Despite strong epidemiologic links between cytokine release syndrome and ICANS, it is uncertain how elevated systemic cytokines and activated immune cells cause brain dysfunction. We previously showed that leukocytes plug brain capillaries in an immunocompetent mouse model of CD19-CAR neurotoxicity. Here, we used the same model to explore how integrin activation and endothelial adhesion molecule expression contribute to capillary plugging. In vivo two-photon imaging revealed increased expression of ICAM-1 on brain capillaries, with spatially restricted VCAM-1 increases. TNF, IFN-γ, and IL-1β at concentrations equivalent to CAR T cell patient blood levels upregulated ICAM-1 and VCAM-1 in brain microendothelial cells. In mice, CAR T cells strongly upregulated VLA-4 (integrin α4β1) affinity to VCAM-1, but not affinity of LFA-1 (integrin αLβ2) to ICAM-1. Blocking integrin α4 but not integrin αL improved ICANS behavior in mice. In human CAR T cell patients, increased soluble ICAM-1 and VCAM-1 are associated with ICANS, and integrin α4 but not integrin αL is upregulated in CAR T cells after infusion. Our study highlights that cytokine-driven upregulation of endothelial-leukocyte adhesion may be sufficient to induce neurovascular dysfunction in CAR T cell patients.
靶向CD19的嵌合抗原受体T细胞(CAR T细胞)可治疗癌症,但也会引发免疫效应细胞相关神经毒性综合征(ICANS)。尽管细胞因子释放综合征与ICANS之间存在紧密的流行病学联系,但尚不清楚全身细胞因子升高和免疫细胞激活如何导致脑功能障碍。我们之前在CD19-CAR神经毒性的免疫活性小鼠模型中发现白细胞会堵塞脑毛细血管。在此,我们使用相同模型来探究整合素激活和内皮黏附分子表达如何导致毛细血管堵塞。体内双光子成像显示脑毛细血管上细胞间黏附分子-1(ICAM-1)表达增加,血管细胞黏附分子-1(VCAM-1)的增加则具有空间局限性。浓度等同于CAR T细胞治疗患者血液水平的肿瘤坏死因子(TNF)、干扰素-γ(IFN-γ)和白细胞介素-1β(IL-1β)可上调脑微血管内皮细胞中的ICAM-1和VCAM-1。在小鼠中,CAR T细胞可强烈上调晚期抗原-4(VLA-4,整合素α4β1)与VCAM-1的亲和力,但不影响淋巴细胞功能相关抗原-1(LFA-1,整合素αLβ2)与ICAM-1的亲和力。阻断整合素α4而非整合素αL可改善小鼠的ICANS症状。在接受CAR T细胞治疗的人类患者中,可溶性ICAM-1和VCAM-1升高与ICANS相关,且输注后CAR T细胞中整合素α4而非整合素αL上调。我们的研究强调,细胞因子驱动的内皮细胞与白细胞黏附上调可能足以在接受CAR T细胞治疗的患者中诱发神经血管功能障碍。